InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA Clue Score57
United States Fiscal year ends December CIK 0001841330
$0.47 +6.03% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.47 −82.16% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 15 Sep 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Revenue0.0Operating income−4.5Net income−2.2EPS, diluted−0.21Fiscal year 2022Revenue0.5 +3,130.4%Operating income−12.6Net income−13.9EPS, diluted−1.76Fiscal year 2023Operating income−16.0Net income−16.0EPS, diluted−0.42Fiscal year 2024Operating income−14.2Net income−13.9EPS, diluted−12.69Fiscal year 2025Operating income−20.9Net income−20.4EPS, diluted−2.91
FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 0.5 n/a n/a n/a
Growth +3,130.4%
Operating income −4.5 −12.6 −16.0 −14.2 −20.9
Net income −2.2 −13.9 −16.0 −13.9 −20.4
Growth
EPS, diluted −0.21 −1.76 −0.42 −12.69 −2.91

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2021Gross margin−14.7%Operating margin−29,925.7%Net margin−14,430.5%Free cash flow margin−21,216.0%Fiscal year 2022Operating margin−2,587.3%Net margin−2,864.3%Free cash flow margin−3,014.8%Fiscal year 2023Fiscal year 2024Fiscal year 2025
FY2021FY2022FY2023FY2024FY2025
Gross margin −14.7% n/a n/a n/a n/a
Operating margin −29,925.7% −2,587.3% n/a n/a n/a
Net margin −14,430.5% −2,864.3% n/a n/a n/a
Free cash flow margin −21,216.0% −3,014.8% n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−3.2Capital expenditure−0.0Free cash flow−3.2Fiscal year 2022Operating cash flow−14.6Capital expenditure−0.1Free cash flow−14.7Fiscal year 2023Operating cash flow−12.8Capital expenditure−0.0Free cash flow−12.8Buybacks−3.7Fiscal year 2024Operating cash flow−13.9Fiscal year 2025Operating cash flow−15.2
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −3.2 −14.6 −12.8 −13.9 −15.2
Capital expenditure −0.0 −0.1 −0.0 n/a n/a
Free cash flow −3.2 −14.7 −12.8 n/a n/a
Growth
Buybacks n/a n/a −3.7 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash53.0Shareholders’ equity51.4Fiscal year 2022Cash33.1Shareholders’ equity42.5Fiscal year 2023Cash16.3Shareholders’ equity23.4Fiscal year 2024Cash6.9Shareholders’ equity14.8Fiscal year 2025Cash55.2Shareholders’ equity55.2
FY2021FY2022FY2023FY2024FY2025
Cash 53.0 33.1 16.3 6.9 55.2
Shareholders’ equity 51.4 42.5 23.4 14.8 55.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−14.7% n/a n/a n/a n/a
−29,925.7% −2,587.3% n/a n/a n/a
−14,430.5% −2,410.4% n/a n/a n/a
−14,430.5% −2,864.3% n/a n/a n/a
−21,216.0% −3,014.8% n/a n/a n/a
Spending
n/a 547.8% n/a n/a n/a
29,911.0% 2,039.5% n/a n/a n/a
142.8% 22.0% n/a n/a n/a
Returns
−4.2% −32.8% −68.2% −94.1% −37.0%
−4.1% −30.8% −61.1% −86.6% −33.9%
Balance and payout
3.6% 5.9% 10.4% 8.0% 8.3%